Stocktoria
Medline Inc. MDLN
Medline Inc. financials (annual)
Bars are annual figures from 2024 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue | $28.4B | $25.5B |
| Gross profit | $7.5B | $7.0B |
| R&D expense | $80.0M | $67.0M |
| SG&A expense | $4.5B | $4.1B |
| Operating income | $2.2B | $2.1B |
| Income tax | $91.0M | $46.0M |
| Net income | $1.2B | — |
| EPS (diluted) | $-0.01 | — |
| Operating cash flow | $1.7B | $1.8B |
| Free cash flow | $1.3B | $1.4B |
| Cash & equivalents | $1.9B | $199.0M |
| Inventory | $4.8B | $4.5B |
| Total assets | $38.5B | $36.0B |
| Total liabilities | $19.2B | $19.5B |
| Shareholders' equity | $19.3B | — |
Growth · year-over-year · Revenue CAGR 11.5%
| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue growth | +11.5% | — |
| Free cash flow growth | -8.3% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.